Bright Minds Biosciences (TSE:DRUG) has released an update.
Bright Minds Biosciences is teaming up again with Firefly Neuroscience to analyze EEG data from their Phase 2 trial of BMB-101, aimed at treating Absence Epilepsy and Developmental Epileptic Encephalopathy. This collaboration leverages advanced AI technology to potentially offer innovative solutions for drug-resistant epilepsy patients. BMB-101 is a promising compound that has shown efficacy in preclinical studies and may provide sustained relief for hard-to-treat epilepsy cases.
For further insights into TSE:DRUG stock, check out TipRanks’ Stock Analysis page.
